Melanoma Management最新文献_第2页

Case report of LVEF derived from gated FDG-PET: potential to streamline cardiotoxic surveillance in melanoma patients. 门控FDG-PET衍生的LVEF病例报告：简化黑色素瘤患者心脏毒性监测的潜力。

IF 1

Melanoma Management Pub Date : 2025-12-01 Epub Date: 2025-05-28 DOI: 10.1080/20450885.2025.2510194

Marc Østergaard Nielsen, Johan Erik Larsson, Linus Daniel Leonhard Duchstein, Lars Thorbjørn Jensen

{"title":"Case report of LVEF derived from gated FDG-PET: potential to streamline cardiotoxic surveillance in melanoma patients.","authors":"Marc Østergaard Nielsen, Johan Erik Larsson, Linus Daniel Leonhard Duchstein, Lars Thorbjørn Jensen","doi":"10.1080/20450885.2025.2510194","DOIUrl":"10.1080/20450885.2025.2510194","url":null,"abstract":"Background: Advances in cancer therapy have improved patient outcomes, but cardiotoxicity remains a significant risk. In melanoma patients treated with BRAF and MEK inhibitors, monitoring left ventricular ejection fraction (LVEF) during treatment is recommended to detect cardiac dysfunction. Despite the widespread use of FDG-PET in oncology, its potential for concurrent cardiac assessment remains underexplored.Methods: A 42-year-old male undergoing treatment for disseminated melanoma underwent measurements of LVEF using four modalities: 3D-MUGA, 3D echocardiography, Rb-PET, and gated FDG-PET.Results: LVEF was within the normal range across all modalities: 60% (3D-MUGA), 61% (3D echocardiography), 63% (Rb-PET), and 65% (FDG-PET).Conclusion: This case presents an estimation of LVEF derived from a clinically indicated, FDG-PET scan, performed alongside three conventional modalities on the same day. This approach may be particularly useful in melanoma patients who undergo frequent FDG-PET scans. While the findings are promising, broader validation is needed.","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"12 1","pages":"2510194"},"PeriodicalIF":1.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12123959/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144175259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeted therapies and PARPi therapy response following ICI therapy failure in advanced melanoma: a case series. 晚期黑色素瘤ICI治疗失败后的靶向治疗和PARPi治疗反应：一个病例系列。

IF 0.7

Melanoma Management Pub Date : 2025-12-01 Epub Date: 2025-12-09 DOI: 10.1080/20450885.2025.2598476

George Nassief, Renee Morecroft, Jordan Phillipps, David Chen, George Ansstas

{"title":"Targeted therapies and PARPi therapy response following ICI therapy failure in advanced melanoma: a case series.","authors":"George Nassief, Renee Morecroft, Jordan Phillipps, David Chen, George Ansstas","doi":"10.1080/20450885.2025.2598476","DOIUrl":"10.1080/20450885.2025.2598476","url":null,"abstract":"Poly (ADP-ribose) polymerase inhibitors (PARPi) have shown efficacy in treating cancers with homologous recombination deficiency (HRD), including subsets of melanoma. However, the potential synergy between PARPi and standard melanoma therapies remains understudied. Here, we report two cases of advanced metastatic melanoma refractory to standard-of-care treatment that demonstrated durable partial responses following the addition of PARPi in combination with immune checkpoint inhibitors (ICIs) and BRAF/MEK inhibitors. Both patients exhibited homologous recombination repair (HRR) pathway mutations and tolerated the combinatory regimens well, achieving progression-free survival of more than 11 months. Mechanistically, PARPi may enhance immunogenicity to ICI therapy via activation of the cyclic GMP-AMP synthase-stimulator of interferon (cGAS-STING) pathway and modulation of programmed death ligand 1 (PD-L1) expression. Preclinical studies also support synergism between PARPi and BRAF/MEK-targeted therapies. This report highlights the potential for PARPi to be integrated into advanced melanoma treatment, particularly in HRD tumors and in combination with ICI and targeted therapies. Although limited by the small sample size, our findings support the rationale for ongoing clinical trials evaluating PARPi-based combinations and underscore the need for further studies to clarify the optimal sequencing and combinations of therapy.","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"12 1","pages":"2598476"},"PeriodicalIF":0.7,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12694906/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145710041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bridging gaps throughout a patient's journey with melanoma: a systematic review. 弥合患者与黑色素瘤之旅的差距：一项系统回顾。

IF 0.7

Melanoma Management Pub Date : 2025-12-01 Epub Date: 2025-10-07 DOI: 10.1080/20450885.2025.2545169

Adil Amarsi, Joy Xu, Josh Chan, Yuan Chun Jiang, Ahmad Zobair Omar, Yasmin Meghdadi, Aashita Doshi, Alison Xie, Alyssa Wu

{"title":"Bridging gaps throughout a patient's journey with melanoma: a systematic review.","authors":"Adil Amarsi, Joy Xu, Josh Chan, Yuan Chun Jiang, Ahmad Zobair Omar, Yasmin Meghdadi, Aashita Doshi, Alison Xie, Alyssa Wu","doi":"10.1080/20450885.2025.2545169","DOIUrl":"10.1080/20450885.2025.2545169","url":null,"abstract":"Background: Melanoma is one of the most fatal skin cancers, with rising incidence and mortality worldwide. From diagnosis to treatment, patient experiences often involve anxiety, symptom burden, and limited access to information which profoundly impacts health outcomes.Objective: This systematic review aims to identify and analyze major barriers melanoma patients face throughout their healthcare journey.Methods: Studies were identified from PubMed, Scopus, Web of Science, Embase, and Cochrane Library, supplemented by manual hand-searching. Eligible studies focused on the experiences of melanoma patients, addressed knowledge gaps and barriers to care throughout the patient journey, and were published in English between 2013 and 2023. Screening and extraction were conducted independently and in duplicate. The methodological quality of the included studies was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria.Results: Out of 2,257 screened articles, 183 met the inclusion criteria. Studies were categorized into four major themes: intersectionality, treatment, diagnosis/prognosis, and patient/societal burden. Commonly explored subcategories included self-examination, risk factors, and drug efficacy.Conclusions: Melanoma patients experience significant gaps throughout their healthcare journey. Identifying areas of improvement in current practices is the first step toward developing targeted solutions that improve the patient experience and quality of life.","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"12 1","pages":"2545169"},"PeriodicalIF":0.7,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12505521/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145240075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Screening and novel diagnostic technologies for melanoma: an update. 黑色素瘤的筛查和新诊断技术：最新进展。

IF 0.7

Melanoma Management Pub Date : 2025-07-20 Epub Date: 2025-07-23 DOI: 10.1080/20450885.2025.2536999

Jonathan C Hwang, Bryan L Peacker, Rebecca I Hartman

引用次数: 0

Updates in clinical trial-explored chemopreventive agents for cutaneous melanoma: mechanisms affecting melanocytes. 皮肤黑色素瘤的临床试验探索化学预防药物的最新进展：影响黑色素细胞的机制。

IF 1

Melanoma Management Pub Date : 2025-05-13 Epub Date: 2025-05-16 DOI: 10.1080/20450885.2025.2505400

Gelare Ghajar-Rahimi, Nabiha Yusuf

{"title":"Updates in clinical trial-explored chemopreventive agents for cutaneous melanoma: mechanisms affecting melanocytes.","authors":"Gelare Ghajar-Rahimi, Nabiha Yusuf","doi":"10.1080/20450885.2025.2505400","DOIUrl":"10.1080/20450885.2025.2505400","url":null,"abstract":"Cutaneous melanoma is a highly aggressive skin cancer with rising incidence, driven by risk factors such as ultraviolet exposure, genetic predisposition, and immunosuppression. While surgical excision remains the primary treatment, interest in chemoprevention strategies is growing. Numerous natural and synthetic agents have shown preclinical promise, but evaluating their effectiveness is challenging due to their systemic effects on multiple cell types. This review provides a focused examination of the melanocyte-specific mechanisms of select agents that have been tested in clinical trials for melanoma chemoprevention. We discuss various molecular and cellular mechanisms driving the anti-melanoma properties of nonsteroidal anti-inflammatory drugs, statins, sulforaphane, vitamin D, and N-acetylcysteine. Despite promising preclinical and early clinical data, challenges remain regarding precise mechanisms, optimal dosing, long-term safety, and patient selection. Future research should focus on refining melanoma prevention strategies through well-designed clinical trials and personalized approaches integrating genetic and molecular risk factors.","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"12 1","pages":"2505400"},"PeriodicalIF":1.0,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12087924/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144081231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A rare and challenging case of amelanotic subungual melanoma from Syria. 来自叙利亚的罕见且具有挑战性的无黑色素瘤趾骨下黑色素瘤病例。

IF 1

Melanoma Management Pub Date : 2024-12-01 Epub Date: 2024-12-29 DOI: 10.1080/20450885.2024.2442874

Muhammad Anas Kudsi, Anas Alsheikh Hamdoun, Osama Haj Osman, Lina Ghabreau, Nour Hakim, Aladdin Etr

引用次数: 0

BRAF-mutant melanoma management: a single center retrospective analysis of patients treated with sequential therapy. braf突变黑色素瘤的管理：单中心回顾性分析患者接受序贯治疗。

IF 1

Melanoma Management Pub Date : 2024-12-01 Epub Date: 2024-11-29 DOI: 10.1080/20450885.2024.2432826

Ilaria Proietti, Elena De Falco, Luca Pacini, Alessandra Spagnoli, Velia Melone, Vincenzo Petrozza, Claudio Di Cristofano, Giorgio Mangino, Giovanna Romeo, Paolo Rosa, Antonella Calogero, Concetta Potenza

{"title":"BRAF-mutant melanoma management: a single center retrospective analysis of patients treated with sequential therapy.","authors":"Ilaria Proietti, Elena De Falco, Luca Pacini, Alessandra Spagnoli, Velia Melone, Vincenzo Petrozza, Claudio Di Cristofano, Giorgio Mangino, Giovanna Romeo, Paolo Rosa, Antonella Calogero, Concetta Potenza","doi":"10.1080/20450885.2024.2432826","DOIUrl":"10.1080/20450885.2024.2432826","url":null,"abstract":"Aims: In treating patients with melanoma, the order in which therapy is administered, choosing between targeted therapy and immune checkpoint inhibition, has garnered growing interest.Patients and methods: We conducted a retrospective, real-world analysis of patients with advanced melanoma undergoing immunotherapy or targeted therapy as first-line at a single center.Results: A total of 88 patients diagnosed with melanoma were identified. At 7 years, in this cohort, 68.4% (95% CI: 55.9%-83.6%) of patients were alive. In all, 47 tumors harbored BRAF mutations; 10 patients who did not receive therapy were excluded from this subgroup. Of the 37 patients with a BRAF mutation, 29 received first-line targeted therapy and 8 received first-line immunotherapy. At 2 years, 28 (76%) patients were alive and 9 (24%) had died. Of the 28 survivors, 22 received first-line targeted therapy and 6 received first-line immunotherapy. In addition, 29 patients were administered a MEK inhibitor in first line. Of these, 66.4% (95% CI: 48.3-91.2) of patients were alive at 7 years.Conclusions: There was no significant difference between survival and first-line immunotherapy or first-line targeted therapy. Additional studies are required to establish whether front-line immunotherapy is linked to more effective long-term disease control compared to first-line targeted therapy.","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"11 1","pages":"2432826"},"PeriodicalIF":1.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11974465/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143053548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immune checkpoint inhibitors in pediatric patients with melanoma: a systematic literature review. 免疫检查点抑制剂在儿童黑色素瘤患者中的应用：系统文献综述。

IF 1

Melanoma Management Pub Date : 2024-12-01 Epub Date: 2024-08-26 DOI: 10.1080/20450885.2024.2382075

Charmy Vyas, Andriy Moshyk, Gina Fusaro, Stergios Zacharoulis, Mir Sohail Fazeli, Nishu Gaind, Shirin Behyan, Pratik Thakkar

引用次数: 0

Melanoma in a Colombian population: a survival study. 哥伦比亚人群中的黑色素瘤：一项生存研究。

IF 1

Melanoma Management Pub Date : 2024-12-01 Epub Date: 2024-08-05 DOI: 10.1080/20450885.2024.2382079

Mauricio Arias Flórez, Germán Alberto Moreno Gómez, Mateo Aguirre Flórez, Isaac López Bueno, Juanita Moreno Gómez, Mateo Moreno Gómez, Juan José Restrepo Gutiérrez

引用次数: 0

Patterns in progression from early-stage melanoma to late-stage melanoma: implications for survivorship follow-up. 从早期黑色素瘤发展到晚期黑色素瘤的模式：对幸存者随访的影响。

IF 1

Melanoma Management Pub Date : 2024-12-01 Epub Date: 2024-12-02 DOI: 10.1080/20450885.2024.2424708

David J Savage, Benjamin Switzer, Rujul Parikh, Jung Min Song, Carolyn Stanek, Joshua Arbesman, Lucy Boyce Kennedy, Pauline Funchain

引用次数: 0